title: Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients.
abstract: OBJECTIVE
  To determine whether a low fat diet supplemented with omega-3 positively affects quality of life (QOL) in relapsing-remitting MS (RRMS) patients. In this 1-year long double-blind, randomized trial, patients were randomized to two dietary interventions: the "Fish Oil" (FO) group received a low fat diet (15% fat) with omega-3 FOs and the "Olive Oil" (OO) group received the AHA Step I diet (fat 30%) with OO supplements. The primary outcome measure was the Physical Components Summary Scale (PCS) of the Short Health Status Questionnaire (SF-36). Additional measures using MS specific QOL questionnaires, neurological status and relapse rate were obtained.
  
  
  RESULTS
  31 RRMS patients were enrolled, with mean follow up over 11 +/- SD 2.9 months. Clinical benefits favoring the FO group were observed on PCS/SF-36 (P = 0.050) and MHI (P = 0.050) at 6 months. Reduced fatigue was seen on the OO diet at 6 months (P = 0.035). The relapse rate decreased in both groups relative to the rates during the 1 year preceding the study: mean change in relapse rate in the FO group: -0.79 +/- SD 1.12 relapses/year (P = 0.021) vs. -0.69 +/- SD 1.11 (P = 0.044) in the OO group. This study suggests that a low fat diet supplemented with omega-3 PUFA can have moderate benefits in RRMS patients on concurrent disease modifying therapies.
authors.affiliation: Baird Multiple Sclerosis Center for MS Treatment and Research, Jacobs Neurological Institute, State University of New York, Buffalo General Hospital-E2, 14203, USA. bweinstock-guttman@kaleidahealth.org
authors.forename: Bianca
authors.initials: B
authors.lastname: Weinstock-Guttman
authors.forename: Monika
authors.initials: M
authors.lastname: Baier
authors.forename: Youngmin
authors.initials: Y
authors.lastname: Park
authors.forename: Joan
authors.initials: J
authors.lastname: Feichter
authors.forename: Peterkin
authors.initials: P
authors.lastname: Lee-Kwen
authors.forename: Eileen
authors.initials: E
authors.lastname: Gallagher
authors.forename: Jaya
authors.initials: J
authors.lastname: Venkatraman
authors.forename: Kulwara
authors.initials: K
authors.lastname: Meksawan
authors.forename: Suzanne
authors.initials: S
authors.lastname: Deinehert
authors.forename: David
authors.initials: D
authors.lastname: Pendergast
authors.forename: Atif B
authors.initials: AB
authors.lastname: Awad
authors.forename: Murali
authors.initials: M
authors.lastname: Ramanathan
authors.forename: Frederick
authors.initials: F
authors.lastname: Munschauer
authors.forename: Richard
authors.initials: R
authors.lastname: Rudick
mesh_terms: D000293:Adolescent; D000328:Adult; D018752:Diet, Fat-Restricted; D019587:Dietary Supplements; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069463:Olive Oil; D010938:Plant Oils / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D013995:Time; D016896:Treatment Outcome
chemical_list: D015525:Fatty Acids, Omega-3; D000069463:Olive Oil; D010938:Plant Oils